echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: Analysis of the safety and efficacy of temozolomide and nabiximols cannabinoid spray in the treatment of recurrent glioblastoma

    Br J Cancer: Analysis of the safety and efficacy of temozolomide and nabiximols cannabinoid spray in the treatment of recurrent glioblastoma

    • Last Update: 2021-03-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Glioblastoma (GBM) is the most common malignant primary brain tumor in adults.
    Its incidence is about 3.
    2 cases per 100,000 people, and the 5-year survival rate of patients is less than 6%.

    Glioblastoma (GBM) is the most common malignant primary brain tumor in adults.
    Its incidence is about 3.
    2 cases per 100,000 people, and the 5-year survival rate of patients is less than 6%.
    Glioblastoma (GBM) is the most common malignant primary brain tumor in adults.
    Its incidence is about 3.
    2 cases per 100,000 people, and the 5-year survival rate of patients is less than 6%.

    Previous studies have shown that GBM is incurable.
    The best treatment at present is to maximize tumor reduction surgery, combined with postoperative local high-dose radiotherapy and temozolomide (TMZ) chemotherapy.
    The average overall survival (OS) of patients receiving this treatment strategy can reach 14.
    6 months.
    However, almost all patients experienced tumor recurrence 6-9 months after treatment.
    The median survival time of patients after relapse has dropped to 1.
    0–10.
    8 months, and there is currently no effective treatment strategy for such patients.


    Cannabinoids are naturally present in the cannabis plant and have been used in medical treatments centuries ago.


    Preclinical data show that certain cannabinoids may exert anti-tumor effects on GBM.



    Test related flowchart

    The first part of the clinical trial is an open, non-blind trial, and the second part is a randomized double-blind trial with a placebo as a control.
    The patient was treated with nabiximols (part 1, n=6; part 2, n=12) or placebo (part 2 only, n=9); a maximum of 12 DIT sprays per day for a duration of up to 12 month.
    Safety, efficacy and pharmacokinetics (PK) of temozolomide are related testing indicators.


    The results showed that the most common treatment-induced adverse events (TEAEs) were vomiting, dizziness, fatigue, nausea and headache.


    Most patients have experienced grade 2 or 3 TEAEs (CTCAE).



    Kaplan-Meier survival curve

    All in all, the study shows that through personalized administration, nabiximols has acceptable safety and tolerability, and no drug interactions have been found.


    The survival differences observed in this trial need to be further verified in follow-up randomized controlled trials.


    Through personalized administration, nabiximols has acceptable safety and tolerability, and no drug interactions have been found.



    org/10.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.